1
|
Codeluppi SA, Xu M, Bansal Y, Lepack AE, Duric V, Chow M, Muir J, Bagot RC, Licznerski P, Wilber SL, Sanacora G, Sibille E, Duman RS, Pittenger C, Banasr M. Prefrontal cortex astroglia modulate anhedonia-like behavior. Mol Psychiatry 2023; 28:4632-4641. [PMID: 37696873 PMCID: PMC10914619 DOI: 10.1038/s41380-023-02246-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Revised: 08/17/2023] [Accepted: 08/29/2023] [Indexed: 09/13/2023]
Abstract
Reductions of astroglia expressing glial fibrillary acidic protein (GFAP) are consistently found in the prefrontal cortex (PFC) of patients with depression and in rodent chronic stress models. Here, we examine the consequences of PFC GFAP+ cell depletion and cell activity enhancement on depressive-like behaviors in rodents. Using viral expression of diphtheria toxin receptor in PFC GFAP+ cells, which allows experimental depletion of these cells following diphtheria toxin administration, we demonstrated that PFC GFAP+ cell depletion induced anhedonia-like behavior within 2 days and lasting up to 8 days, but no anxiety-like deficits. Conversely, activating PFC GFAP+ cell activity for 3 weeks using designer receptor exclusively activated by designer drugs (DREADDs) reversed chronic restraint stress-induced anhedonia-like deficits, but not anxiety-like deficits. Our results highlight a critical role of cortical astroglia in the development of anhedonia and further support the idea of targeting astroglia for the treatment of depression.
Collapse
Affiliation(s)
- S A Codeluppi
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - M Xu
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Y Bansal
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - A E Lepack
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - V Duric
- Department of Psychiatry, Yale University, New Haven, CT, USA
- Department of Physiology and Pharmacology, Des Moines University, West Des Moines, IA, USA
| | - M Chow
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - J Muir
- Integrated Program in Neuroscience, McGill University, Montréal, QC, Canada
| | - R C Bagot
- Department of Psychology, McGill University, Montreal, QC, Canada
- Ludmer Centre for Neuroinformatics and Mental Health, Montreal, QC, Canada
| | - P Licznerski
- Department of Psychiatry, Yale University, New Haven, CT, USA
- Department of Internal Medicine, Section of Endocrinology, Yale University, New Haven, CT, USA
| | - S L Wilber
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - G Sanacora
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - E Sibille
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - R S Duman
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - C Pittenger
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - M Banasr
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
- Department of Psychiatry, Yale University, New Haven, CT, USA.
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
2
|
Codeluppi S, Xu M, Bansal Y, Lepack A, Duric V, Chow M, Muir. J, Bagot R, Licznerski P, Wilber S, Sanacora G, Sibille E, Duman R, Pittenger C, Banasr M. Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior. Res Sq 2023:rs.3.rs-3093428. [PMID: 37461693 PMCID: PMC10350119 DOI: 10.21203/rs.3.rs-3093428/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Abstract
Reductions of astroglia expressing glial fibrillary acidic protein (GFAP) are consistently found in the prefrontal cortex (PFC) of patients with depression and in rodent chronic stress models. Here, we examine the consequences of PFC GFAP+ cell depletion and cell activity enhancement on depressive-like behaviors in rodents. Using viral expression of diphtheria toxin receptor in PFC GFAP+ cells, which allows experimental depletion of these cells following diphtheria toxin administration, we demonstrated that PFC GFAP+ cell depletion induced anhedonia-like behavior within 2 days and lasting up to 8 days, but no anxiety-like deficits. Conversely, activating PFC GFAP+ cell activity for 3 weeks using designer receptor exclusively activated by designer drugs (DREADDs) reversed chronic restraint stress-induced anhedonia-like deficits, but not anxiety-like deficits. Our results highlight a critical role of cortical astroglia in the development of anhedonia and further support the idea of targeting astroglia for the treatment of depression.
Collapse
Affiliation(s)
- S.A. Codeluppi
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
| | - M. Xu
- Department of Psychiatry, Yale University, New Haven, USA
| | - Y. Bansal
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
| | - A.E. Lepack
- Department of Psychiatry, Yale University, New Haven, USA
| | - V. Duric
- Department of Psychiatry, Yale University, New Haven, USA
- Department of Physiology and Pharmacology, Des Moines University, Iowa, USA
| | - M. Chow
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
| | - J. Muir.
- Integrated Program in Neuroscience, McGill University, Montréal, Canada
| | - R.C. Bagot
- Department of Psychology, McGill University, Montreal, Canada
- Ludmer Centre for Neuroinformatics and Mental Health, Montreal, QC, Canada
| | - P. Licznerski
- Department of Psychiatry, Yale University, New Haven, USA
- Department of Internal Medicine, Section of Endocrinology, Yale University, New Haven, USA
| | - S.L. Wilber
- Department of Psychiatry, Yale University, New Haven, USA
| | - G. Sanacora
- Department of Psychiatry, Yale University, New Haven, USA
| | - E. Sibille
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | - R.S. Duman
- Department of Psychiatry, Yale University, New Haven, USA
| | - C. Pittenger
- Department of Psychiatry, Yale University, New Haven, USA
| | - M. Banasr
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
- Department of Psychiatry, Yale University, New Haven, USA
- Department of Psychiatry, University of Toronto, Toronto, Canada
| |
Collapse
|
3
|
Licznerski P, Duman RS. Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 2012; 251:33-50. [PMID: 23036622 DOI: 10.1016/j.neuroscience.2012.09.057] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Revised: 09/10/2012] [Accepted: 09/22/2012] [Indexed: 01/22/2023]
Abstract
Dendritic spines provide a compartment for assembly and functional organization of synaptic machinery that plays a fundamental role in neuronal communication and neuroplasticity. Studies in humans as well as in animal models have demonstrated abnormal spine architecture in several psychiatric disorders, including depression and other stress-related illnesses. The negative impact of stress on the density and organization of spines is thought to contribute to the behavioral deficits caused by stress exposure. Moreover, there is now evidence that medication-induced recovery involves changes in synaptic plasticity and dendrite morphology, including increased expression of pre- and postsynaptic plasticity-related proteins, as well as the density and function of axo-spinous synapses. Here we review the evidence from brain imaging and postmortem studies demonstrating that depression is accompanied by structural and functional alterations of cortical and limbic brain regions, including the prefrontal cortex, hippocampus and amygdala. In addition, we present more direct evidence from basic research studies that exposure to stress alters spine morphology, function and plasticity and that antidepressants, particularly new rapid acting agents, reverse these effects. Elucidation of the signaling pathways and molecular mechanisms that control spine synapse assembly and plasticity will contribute to a better understanding of the pathophysiology of depression and development of novel, more effective therapeutic agents.
Collapse
Affiliation(s)
- P Licznerski
- Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT 06508, United States
| | | |
Collapse
|